Kymera CBO sells 3,389 shares under 10b5-1 plan

Kymera Therapeutics Chief Business Officer Noah Goodman sold 3,389 shares of common stock in an open-market transaction at $114.29 per share.

Accepted by SEC EDGAR 07/02/2026 - 06:30 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kymera Therapeutics Chief Business Officer Noah Goodman sold 3,389 shares of common stock in an open-market transaction at $114.29 per share. The trade was executed under a pre-arranged Rule 10b5-1 trading plan dated December 10, 2025. Following the sale, Goodman directly holds 47,179.438 shares, which includes 373 shares acquired through Kymera’s employee stock purchase plan.

Insider Trade Summary 10b5-1

Net Seller: 3,389 shares

Net Sell 1 txn

Insider Goodman Noah

Role Chief Business Officer

Sold 3,389 shs ($387K)

Share of Position Sold 6.7%

Type	Security	Shares	Price	Value
Sale	Common Stock	3,389	$114.29	$387K

Holdings After Transaction: Common Stock — 47,179.438 shares (Direct)

Holdings Before and After: Common Stock, 50,568.438 to 47,179.438 shares (Direct)

Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.
2. F2. This number includes 373 shares acquired under the Registrant's employee stock purchase plan.

Key Figures

Shares sold: 3,389 shares Sale price per share: $114.29 per share Shares held after transaction: 47,179.438 shares +2 more

5 metrics

Shares sold 3,389 shares Open-market sale of common stock

Sale price per share $114.29 per share Price for the 3,389 shares sold

Shares held after transaction 47,179.438 shares Direct holdings following the sale

ESPP shares included 373 shares Portion of post-transaction holdings from employee stock purchase plan

Transaction date July 1, 2026 Date of the open-market sale

Key Terms

Rule 10b5-1 trading plan, employee stock purchase plan, open-market sale, Form 4

4 terms

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

employee stock purchase plan financial

"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

open-market sale financial

"transaction_action: open-market sale"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Kymera Therapeutics (KYMR) report for Noah Goodman?

Kymera Therapeutics reported that Chief Business Officer Noah Goodman sold 3,389 shares of common stock at $114.29 per share. The transaction was an open-market sale executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 10, 2025.

How many Kymera (KYMR) shares does Noah Goodman hold after this Form 4 transaction?

After the reported sale, Noah Goodman directly holds 47,179.438 Kymera shares. This figure includes 373 shares acquired under the company’s employee stock purchase plan, giving investors a clear view of his remaining equity stake following the open-market sale.

Was the Kymera (KYMR) insider sale by Noah Goodman under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan dated December 10, 2025. Such plans pre-schedule trades, indicating this sale was part of an established program rather than a discretionary, opportunistic transaction.

What price did Noah Goodman receive per share in his Kymera (KYMR) stock sale?

The reported sale price was $114.29 per Kymera share. This per-share price applies to the 3,389 common shares sold in the open market, as disclosed in the Form 4, and provides transparency into the valuation level at which the trade occurred.

Does Noah Goodman’s Kymera (KYMR) Form 4 mention employee stock purchase plan shares?

Yes. A footnote explains that his post-transaction holding of 47,179.438 shares includes 373 shares acquired under Kymera’s employee stock purchase plan. This clarifies that a portion of his stake comes from ongoing employee share purchase participation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Goodman Noah

(Last) (First) (Middle)

500 NORTH BEACON STREET

4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/01/2026		S(1)		3,389	D	$114.29	47,179.438(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person.

2. This number includes 373 shares acquired under the Registrant's employee stock purchase plan.

	/s/ Bruce Jacobs, as Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)